The Pharmaceutical Journal
Vol 275 No 7364 p245
27 August 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Chemotherapy for obese women

Chemotherapy doses for obese women with oestrogen receptor-negative breast cancer should not be reduced routinely, say researchers.

Clinicians often reduce chemotherapy doses in this group of women because of concerns about toxicity, but this practice was found to be detrimental in women whose tumours are low in oestrogen receptors. The study was published online in The Lancet on 24 August.